-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 6th, the World Health Organization updated its patient care guidelines to include interleukin-6 receptor antagonists
In September 2020, the World Health Organization recommended the use of corticosteroids, which is another effective drug recommended by the World Health Organization for the treatment of new coronary pneumonia
Combining data from more than 10,000 patients in 27 clinical trials, WHO has conducted the largest analysis of such drugs to date
Critically ill patients with new coronary pneumonia often have an overreaction of the immune system, which may seriously damage the health of the patient
Analysis shows that compared with standard treatment, the use of interleukin-6 receptor antagonists in severe or critically ill patients with new coronary pneumonia can reduce the mortality rate by 13%, that is, the number of deaths per thousand severely ill patients will be reduced by 15 people per thousand.
WHO Director-General Tan Desai said: "These drugs bring hope to critically ill patients with new coronary pneumonia and their families
In order to improve the accessibility and affordability of these "life-saving medicines", WHO calls on manufacturers to lower prices and provide such medicines to low- and middle-income countries, especially those with a surge in new coronary pneumonia cases
In addition, WHO also encourages pharmaceutical companies to accept transparent, non-exclusive voluntary licensing agreements, or to abandon drug patents
